188 related articles for article (PubMed ID: 37719859)
1. Heterogeneity and potential therapeutic insights for triple-negative breast cancer based on metabolic-associated molecular subtypes and genomic mutations.
Li L; Wu N; Zhuang G; Geng L; Zeng Y; Wang X; Wang S; Ruan X; Zheng X; Liu J; Gao M
Front Pharmacol; 2023; 14():1224828. PubMed ID: 37719859
[No Abstract] [Full Text] [Related]
2. Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy.
Zhou Y; Che Y; Fu Z; Zhang H; Wu H
Front Public Health; 2022; 10():902378. PubMed ID: 35875026
[TBL] [Abstract][Full Text] [Related]
3. Essential amino acid metabolism-related molecular classification in triple-negative breast cancer.
Zhao Y; Pu C; Jiao D; Zhu J; Guo X; Liu Z
Epigenomics; 2021 Aug; 13(16):1247-1268. PubMed ID: 34448400
[TBL] [Abstract][Full Text] [Related]
4. Immune Classification and Immune Landscape Analysis of Triple-Negative Breast Cancer.
Hu S; Qu X; Jiao Y; Hu J; Wang B
Front Genet; 2021; 12():710534. PubMed ID: 34795691
[No Abstract] [Full Text] [Related]
5. Combination of Immune-Related Network and Molecular Typing Analysis Defines a Three-Gene Signature for Predicting Prognosis of Triple-Negative Breast Cancer.
Zhang J; Pan S; Han C; Jin H; Sun Q; Du J; Han X
Biomolecules; 2022 Oct; 12(11):. PubMed ID: 36358906
[TBL] [Abstract][Full Text] [Related]
6. Immunity and Extracellular Matrix Characteristics of Breast Cancer Subtypes Based on Identification by T Helper Cells Profiling.
Zhou Y; Tian Q; Gao H; Zhu L; Zhang Y; Zhang C; Yang J; Wang B
Front Immunol; 2022; 13():859581. PubMed ID: 35795662
[TBL] [Abstract][Full Text] [Related]
7. A senescence-associated signature refines the classification of different modification patterns and characterization of tumor immune microenvironment infiltration in triple-negative breast cancer.
Huang R; Wang H; Hong J; Wang Z; Wu J; Huang O; He J; Chen W; Li Y; Chen X; Shen K
Front Pharmacol; 2023; 14():1191910. PubMed ID: 37251343
[No Abstract] [Full Text] [Related]
8. Establishment of a novel cytokine-related 8-gene signature for distinguishing and predicting the prognosis of triple-negative breast cancer.
Liu X; Zhang L; Chen L
Front Med (Lausanne); 2023; 10():1189361. PubMed ID: 37332770
[TBL] [Abstract][Full Text] [Related]
9. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.
Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM
Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.
Elfgen C; Reeve K; Moskovszky L; Güth U; Bjelic-Radisic V; Fleisch M; Tausch C; Varga Z
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2051-2059. PubMed ID: 31270600
[TBL] [Abstract][Full Text] [Related]
11. Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis.
Ma J; Chen C; Liu S; Ji J; Wu D; Huang P; Wei D; Fan Z; Ren L
Cancer Gene Ther; 2022 Nov; 29(11):1578-1589. PubMed ID: 35474355
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel glycolysis-related prognosis risk signature in triple-negative breast cancer.
Ruan Y; Tang Q; Qiao J; Wang J; Li H; Yue X; Sun Y; Wang P; Yang H; Liu Z
Front Oncol; 2023; 13():1171496. PubMed ID: 37274269
[TBL] [Abstract][Full Text] [Related]
13. Transcriptome-Based Network Analysis Unveils Eight Immune-Related Genes as Molecular Signatures in the Immunomodulatory Subtype of Triple-Negative Breast Cancer.
Zhang J; Wang L; Xu X; Li X; Guan W; Meng T; Xu G
Front Oncol; 2020; 10():1787. PubMed ID: 33042828
[No Abstract] [Full Text] [Related]
14. Characterization of Hypoxia-Related Molecular Subtypes in Clear Cell Renal Cell Carcinoma to Aid Immunotherapy and Targeted Therapy
Zhong W; Zhong H; Zhang F; Huang C; Lin Y; Huang J
Front Mol Biosci; 2021; 8():684050. PubMed ID: 34250018
[No Abstract] [Full Text] [Related]
15. A pyroptosis-associated gene risk model for predicting the prognosis of triple-negative breast cancer.
Qiu P; Guo Q; Pan K; Chen J; Lin J
Front Oncol; 2022; 12():890242. PubMed ID: 36276158
[TBL] [Abstract][Full Text] [Related]
16. The Identification of the Metabolism Subtypes of Skin Cutaneous Melanoma Associated With the Tumor Microenvironment and the Immunotherapy.
Yang R; Wang Z; Li J; Pi X; Gao R; Ma J; Qing Y; Zhou S
Front Cell Dev Biol; 2021; 9():707677. PubMed ID: 34458265
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancer.
Lin F; Huang J; Zhu W; Jiang T; Guo J; Xia W; Chen M; Guo L; Deng W; Lin H
Front Immunol; 2023; 14():1218987. PubMed ID: 37575241
[TBL] [Abstract][Full Text] [Related]
18. Triple Negative Breast Cancer: Molecular Subtype-Specific Immune Landscapes with Therapeutic Implications.
Syrnioti A; Petousis S; Newman LA; Margioula-Siarkou C; Papamitsou T; Dinas K; Koletsa T
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893213
[TBL] [Abstract][Full Text] [Related]
19. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
[TBL] [Abstract][Full Text] [Related]
20. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
